[go: up one dir, main page]

MX2018008694A - Metodos y composiciones para tratar la hiperhidrosis. - Google Patents

Metodos y composiciones para tratar la hiperhidrosis.

Info

Publication number
MX2018008694A
MX2018008694A MX2018008694A MX2018008694A MX2018008694A MX 2018008694 A MX2018008694 A MX 2018008694A MX 2018008694 A MX2018008694 A MX 2018008694A MX 2018008694 A MX2018008694 A MX 2018008694A MX 2018008694 A MX2018008694 A MX 2018008694A
Authority
MX
Mexico
Prior art keywords
muscarinic antagonist
methods
compositions
subject
practicing
Prior art date
Application number
MX2018008694A
Other languages
English (en)
Other versions
MX394356B (es
Inventor
F Mcgraw Benjamin Iii
Original Assignee
Theravida Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Theravida Inc filed Critical Theravida Inc
Publication of MX2018008694A publication Critical patent/MX2018008694A/es
Publication of MX394356B publication Critical patent/MX394356B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5084—Mixtures of one or more drugs in different galenical forms, at least one of which being granules, microcapsules or (coated) microparticles according to A61K9/16 or A61K9/50, e.g. for obtaining a specific release pattern or for combining different drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
    • A61K9/5042—Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
    • A61K9/5047—Cellulose ethers containing no ester groups, e.g. hydroxypropyl methylcellulose
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Dermatology (AREA)

Abstract

Los aspectos de la descripción incluyen métodos para tratar hiperhidrosis en un sujeto con una composición que incluye un antagonista muscarínico y un antagonista muscarínico. Al poner en práctica los métodos según ciertas realizaciones, una cantidad terapéuticamente eficaz de una composición que incluye un antagonista muscarínico, o una sal farmacéuticamente aceptable del mismo, y un antagonista muscarínico, o una sal farmacéuticamente aceptable del mismo, se administra a un sujeto, y es suficiente para reducir la hiperhidrosis en el sujeto y para reducir un efecto secundario de sequedad de boca del antagonista muscarínico. También se describen composiciones para poner en práctica los presentes métodos, así como unidades de dosis que contienen una o más de las presentes composiciones.
MX2018008694A 2016-01-20 2016-01-20 Métodos y composiciones para tratar hiperhidrosis. MX394356B (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/US2016/014150 WO2017127073A1 (en) 2016-01-20 2016-01-20 Methods and compositions for treating hyperhidrosis

Publications (2)

Publication Number Publication Date
MX2018008694A true MX2018008694A (es) 2019-05-15
MX394356B MX394356B (es) 2025-03-24

Family

ID=59314209

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2018008694A MX394356B (es) 2016-01-20 2016-01-20 Métodos y composiciones para tratar hiperhidrosis.

Country Status (15)

Country Link
US (4) US10328057B2 (es)
EP (1) EP3405191B1 (es)
JP (1) JP6841834B2 (es)
KR (2) KR102495757B1 (es)
CN (1) CN108697688A (es)
AU (2) AU2016388308B2 (es)
BR (1) BR112018014661A2 (es)
CA (1) CA3011683C (es)
DK (1) DK3405191T3 (es)
HK (1) HK1258825A1 (es)
MX (1) MX394356B (es)
RU (1) RU2718906C2 (es)
TW (2) TWI810150B (es)
WO (1) WO2017127073A1 (es)
ZA (1) ZA201805490B (es)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10265311B2 (en) 2009-07-22 2019-04-23 PureTech Health LLC Methods and compositions for treatment of disorders ameliorated by muscarinic receptor activation
EP3061821B1 (en) 2009-07-22 2019-07-10 Puretech Health LLC Compositions for treatment of disorders ameliorated by muscarinic receptor activation
GB2479213B (en) 2010-04-01 2013-07-10 Theravida Inc Pharmaceutical formulations for the treatment of overactive bladder
DK3405191T3 (da) 2016-01-20 2025-05-19 Theravida Inc Sammensætninger til anvendelse ved behandling af hyperhidrose
EP3856182B1 (en) 2018-09-28 2025-12-24 Karuna Therapeutics, Inc. Compositions and methods for treating disorders ameliorated by muscarnic receptor activation
EP3993646B1 (en) 2019-07-05 2023-08-16 Swedish Match North Europe AB An oral pouched nicotine product including a filling material comprising nicotine-containing particles
KR102849937B1 (ko) 2019-11-20 2025-08-25 스웨디쉬 매치 노스 유럽 에이비 니코틴 입자를 포함하는 충전 재료를 포함하는 경구 파우치형 니코틴 제품
EP3967311A1 (en) * 2020-09-11 2022-03-16 Astellas Pharma Inc. Compounds for use in the treatment of dry mouth
PL4018848T3 (pl) 2020-12-22 2024-11-25 Swedish Match North Europe Ab Wyrób w saszetkach do użytku doustnego zawierający materiał pokrywający przepuszczalny dla cieczy oraz materiał wypełniający
PL4018849T3 (pl) 2020-12-22 2025-02-10 Swedish Match North Europe Ab Wyrób w saszetkach do użytku doustnego
EP4018847B1 (en) 2020-12-22 2024-09-18 Swedish Match North Europe AB A pouched product for oral use
AU2022326451A1 (en) * 2021-08-11 2024-02-08 Theravida, Inc. Pharmaceutical compositions and methods for treating hyperhidrosis
TR2023000985A2 (tr) * 2023-01-27 2023-02-21 Ardi̇ Farma İlaç Pazarlama Ti̇caret Li̇mi̇ted Şi̇rketi̇ Kontrollü salim sağlayan propi̇veri̇n formülasyonu

Family Cites Families (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4209505A (en) 1979-04-03 1980-06-24 Mikhail Adib R Pilocarpine mouthwash for dry mouth relief
US4302440B1 (en) * 1980-07-31 1986-08-05 Easily-swallowed, powder-free and gastric-disintegrable aspirin tablet thinly-coated with hydroxypropyl methylcellulose and aqueous spray-coating preparation thereof
SE450087B (sv) 1985-10-11 1987-06-09 Haessle Ab Korn med kontrollerad frisettning av farmaceutiskt aktiva emnen som anbringats teckande pa ett kompakt olosligt kernmaterial
PH30929A (en) 1992-09-03 1997-12-23 Janssen Pharmaceutica Nv Beads having a core coated with an antifungal and a polymer.
US6096756A (en) 1992-09-21 2000-08-01 Albert Einstein College Of Medicine Of Yeshiva University Method of simultaneously enhancing analgesic potency and attenuating dependence liability caused by morphine and other bimodally-acting opioid agonists
US6787156B1 (en) 1994-02-23 2004-09-07 Bm Research A/S Controlled release composition
US5674895A (en) 1995-05-22 1997-10-07 Alza Corporation Dosage form comprising oxybutynin
GB9518953D0 (en) 1995-09-15 1995-11-15 Pfizer Ltd Pharmaceutical formulations
CA2277220A1 (en) 1997-01-10 1998-07-16 Abbott Laboratories Tablet for the controlled release of active agents
EP0969821B1 (en) * 1997-03-26 2003-06-04 Janssen Pharmaceutica N.V. Pellets having a core coated with an antifungal and a polymer
UA53774C2 (uk) 1997-12-22 2003-02-17 Еро-Селтік, С.А. Спосіб запобігання зловживанню лікарськими формами, що містять опіоїди
CA2314893C (en) 1997-12-22 2005-09-13 Euro-Celtique, S.A. Opioid agonist/antagonist combinations
US6482837B1 (en) 1998-04-24 2002-11-19 University Of Rochester Antimuscarinic compounds and methods for treatment of bladder diseases
US5997905A (en) 1998-09-04 1999-12-07 Mcneil-Ppc Preparation of pharmaceutically active particles
EP1125586A4 (en) 1998-10-26 2003-06-11 Tanabe Seiyaku Co EXTENDED RELEASE PARTICLE
FR2795962B1 (fr) 1999-07-08 2003-05-09 Prographarm Laboratoires Procede de fabrication de granules enrobes a gout masque et liberation immediate du principe actif
CN101288663A (zh) 1999-09-14 2008-10-22 史密丝克莱恩比彻姆公司 制备水性包被小球粒的方法
KR100838930B1 (ko) 1999-11-11 2008-06-16 화이자 헬스 에이비 톨테로딘을 포함하는 약학 제제 및 이의 용도
AU2710301A (en) 2000-01-28 2001-08-07 Asahi Kasei Kabushiki Kaisha Novel remedies with the use of beta3 agonist
US6716449B2 (en) 2000-02-08 2004-04-06 Euro-Celtique S.A. Controlled-release compositions containing opioid agonist and antagonist
US6419954B1 (en) 2000-05-19 2002-07-16 Yamanouchi Pharmaceutical Co., Ltd. Tablets and methods for modified release of hydrophilic and other active agents
US20030044458A1 (en) 2001-08-06 2003-03-06 Curtis Wright Oral dosage form comprising a therapeutic agent and an adverse-effect agent
WO2003082207A2 (en) 2002-03-29 2003-10-09 Alza Corporation Volume efficient controlled release dosage form
FR2842735B1 (fr) 2002-07-26 2006-01-06 Flamel Tech Sa Microcapsules a liberation modifiee de principes actifs peu solubles pour l'administration per os
FR2842736B1 (fr) 2002-07-26 2005-07-22 Flamel Tech Sa Formulation pharmaceutique orale sous forme d'une pluralite de microcapsules permettant la liberation prolongee de principe(s) actif(s) peu soluble(s)
US9107804B2 (en) 2002-12-10 2015-08-18 Nortec Development Associates, Inc. Method of preparing biologically active formulations
EP1635795A1 (en) 2003-05-30 2006-03-22 Ranbaxy Laboratories, Ltd. Controlled release pharmaceutical compositions of tolterodine and processes for their preparation
CN1845725A (zh) 2003-08-06 2006-10-11 尼马尔·穆利耶 包含水溶性药物的药物组合物
JP5610663B2 (ja) 2003-11-04 2014-10-22 スパーナス ファーマシューティカルズ インコーポレイテッド トロスピウムの１日１回剤形
CA2579767A1 (en) 2004-04-30 2005-11-10 Astellas Pharma Inc. Oral pharmaceutical composition in timed-release particle form and fast-disintegrating tablets containing this composition
CA2566311A1 (en) 2004-05-19 2005-12-08 Glatt Air Techniques, Inc. Micropellet containing pellets and method of preparing such pellets
EP1753405A4 (en) 2004-06-10 2008-09-17 Glatt Air Tech Inc SLOW RELEASE PHARMACEUTICAL PREPARATION
JP2008516893A (ja) 2004-08-27 2008-05-22 スフェリックス，インク． 多層錠剤および生体接着性剤形
EP1629834A1 (en) 2004-08-27 2006-03-01 KRKA, D.D., Novo Mesto Sustained release pharmaceutical composition of tolterodine
WO2006132196A1 (ja) 2005-06-08 2006-12-14 Asahi Kasei Pharma Corporation β３作動薬を含有する新規な医薬
EP1933833B8 (en) 2005-09-02 2011-09-14 Theravida, Inc. Therapy for the treatment of overactive bladder
WO2007029087A2 (en) 2005-09-05 2007-03-15 Ranbaxy Laboratories Limited Controlled release multiple unit formulations
US20070077300A1 (en) 2005-09-30 2007-04-05 Wynn David W Oral compositions containing a salivation inducing agent
EP1951186A4 (en) * 2005-10-19 2009-11-04 Menni Menashe Zinger METHODS FOR TREATING HYPERHIDROSIS
CA2680680A1 (en) 2007-03-29 2009-02-19 Panacea Biotec Limited Modified dosage forms of tacrolimus
US7563508B2 (en) 2007-05-30 2009-07-21 Chung Shan Institute Of Science And Technology, Armaments Bureau, M.N.D. Diffusion beads with core-shell structure
WO2009003724A1 (en) 2007-07-03 2009-01-08 Synthon B.V. Tolterodine bead
US8110226B2 (en) 2007-07-20 2012-02-07 Mylan Pharmaceuticals Inc. Drug formulations having inert sealed cores
WO2009019599A2 (en) 2007-08-08 2009-02-12 Themis Laboratories Private Limited Extended release compositions comprising tolterodine
US9561015B2 (en) * 2007-08-24 2017-02-07 General Electric Company Method and apparatus for voice recording with ultrasound imaging
BRPI0817275A2 (pt) 2007-09-28 2015-06-16 Novartis Ag Combinação farmacêutica de alisquireno e valsartana
JP2011502140A (ja) 2007-10-29 2011-01-20 ルピン・リミテッド トルテロジンの制御放出型医薬組成物
US20090192228A1 (en) 2008-01-28 2009-07-30 Actavis Group Ptc Ehf Controlled-Release Tolterodine Compositions and Methods
WO2009151712A2 (en) * 2008-03-25 2009-12-17 Auspex Pharmaceuticals. Inc. Substituted phenylcyclohexylglycolates
CN102939008A (zh) 2010-04-01 2013-02-20 塞拉维达公司 改善睡眠质量的方法
GB2479213B (en) 2010-04-01 2013-07-10 Theravida Inc Pharmaceutical formulations for the treatment of overactive bladder
RU2671575C2 (ru) 2011-05-10 2018-11-02 Теравида, Инк. Применение солифенацина и стимуляторов слюноотделения в лечении гиперактивного мочевого пузыря
WO2012154770A1 (en) 2011-05-10 2012-11-15 Theravida, Inc. Combinations of tolterodine and salivary stimulants for the treatment of overactive bladder
US20140037713A1 (en) * 2012-08-03 2014-02-06 Antares Pharma Ipl, Ag Transdermal compositions for anti-cholinergic agents
WO2014059309A1 (en) 2012-10-11 2014-04-17 Theravida, Inc. Pharmaceutical formulations of pilocarpine
DK3405191T3 (da) 2016-01-20 2025-05-19 Theravida Inc Sammensætninger til anvendelse ved behandling af hyperhidrose

Also Published As

Publication number Publication date
KR102600541B1 (ko) 2023-11-08
JP6841834B2 (ja) 2021-03-10
RU2718906C2 (ru) 2020-04-15
US20200188360A1 (en) 2020-06-18
KR20230021184A (ko) 2023-02-13
EP3405191A1 (en) 2018-11-28
US10610519B2 (en) 2020-04-07
US20190307727A1 (en) 2019-10-10
CA3011683A1 (en) 2017-07-27
US10328057B2 (en) 2019-06-25
KR20180102649A (ko) 2018-09-17
TWI810150B (zh) 2023-08-01
US20220047558A1 (en) 2022-02-17
EP3405191B1 (en) 2025-02-19
TW202341976A (zh) 2023-11-01
JP2019506401A (ja) 2019-03-07
DK3405191T3 (da) 2025-05-19
KR102495757B1 (ko) 2023-02-06
TW201737906A (zh) 2017-11-01
AU2016388308A1 (en) 2018-08-02
US20170202778A1 (en) 2017-07-20
CA3011683C (en) 2023-09-26
US11779569B2 (en) 2023-10-10
US11185533B2 (en) 2021-11-30
RU2018128047A3 (es) 2020-02-20
ZA201805490B (en) 2019-11-27
EP3405191A4 (en) 2019-09-04
BR112018014661A2 (pt) 2018-12-11
WO2017127073A1 (en) 2017-07-27
RU2018128047A (ru) 2020-02-20
AU2016388308B2 (en) 2022-08-04
CN108697688A (zh) 2018-10-23
MX394356B (es) 2025-03-24
AU2022206709A1 (en) 2022-08-11
HK1258825A1 (zh) 2019-11-22

Similar Documents

Publication Publication Date Title
MX2018008694A (es) Metodos y composiciones para tratar la hiperhidrosis.
CL2019003542A1 (es) Métodos de tratamiento para la fibrosis quística.
CL2021001292A1 (es) Terapia de combinación que incluye un inhibidor de krasg12c y uno o más agentes farmacéuticamente activos adicionales para el tratamiento de cánceres
MX394252B (es) Tratamiento del cancer usando combinaciones de inhibidores de erk y raf
AR121843A2 (es) Formulación oftálmica y método para mejorar la presbicia
CO2019009423A2 (es) Inhibidores de mnk sustituidos con piperidina y métodos relacionados con los mismos
MX2020003415A (es) Compuestos de benzoxacepina oxazolidinona y métodos de uso.
PE20171241A1 (es) Terapias de combinacion para el tratamiento de canceres
CO2018009561A2 (es) Métodos para tratar la depresión con antagonistas del receptor de orexina-2
MX2019007587A (es) Composicion oftalmica para el tratamiento de la enfermedad del ojo seco.
MX2016016380A (es) Composicion farmaceutica para usarse en la prevencion y/o tratamiento de enfermedades que se desarrollan o progresan como resultado de una disminucion o perdida de actividad del factor viii de coagulacion sanguinea activado.
MX2009006786A (es) Composiciones y metodos para el tratamiento de infecciones y tumores.
PE20142314A1 (es) Composiciones intranasales de dexmedetomidina y metodos de uso de ellas
MX2018016330A (es) Combinaciones para tratamiento del cáncer.
CU20160169A7 (es) Compuestos y composiciones para inducir condrogénesis
MX376312B (es) Uso de antagonistas del receptor ep4 para el tratamiento de cancer de higado asociado con nash
AR096892A1 (es) Una combinación farmacéutica para el tratamiento del melanoma
CR20110648A (es) Compuestos heterocíclicos de fenoximetilo
MX2016015437A (es) Combinacion que comprende un glucocorticoide y edo-s101.
MX383159B (es) Composiciones y métodos para el uso de eflornitina, y derivados y análogos de la misma para tratar cánceres, incluyendo gliomas
MX2017011499A (es) Combinaciones de dosis fija y formulaciones que comprenden ácido 8-hidroxi-2,2,14,14 tetrametilpentadecanodioico (etc1002) y ezetimiba y métodos para tratar o reducir el riesgo de enfermedad cardiovascular.
BR112017004580A2 (pt) composto, composição farmacêutica, produto de combinação, uso de um composto ou sal farmaceuticamente aceitável, e, método de tratamento.
MX2018014129A (es) Composiciones farmaceuticas de oligomero de morfolino fosforodiamidato.
UY35890A (es) Uso de laquinimod para retrasar la progresión de la enfermedad de huntington
MX2015012716A (es) Composiciones para el uso en el tratamiento de trastornos oculares que usan dipiridamol.